Requests that the FDA declare that Cyproheptadine Hydrochloride Orally Disintegrating Tablets, 2 mg, 3 mg, 4 mg and 6 mg is suitable for submission as an ANDA.
🏛 Food and Drug Administration (FDA)FDA-2026-P-6811
Documents
6
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
- Other· Jun 25, 2026No comment period
- Other· Jun 16, 2026No comment period
- Other· Jun 16, 2026No comment period